IL111730A - Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them - Google Patents

Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them

Info

Publication number
IL111730A
IL111730A IL11173094A IL11173094A IL111730A IL 111730 A IL111730 A IL 111730A IL 11173094 A IL11173094 A IL 11173094A IL 11173094 A IL11173094 A IL 11173094A IL 111730 A IL111730 A IL 111730A
Authority
IL
Israel
Prior art keywords
mass
nmr
group
dmso
bis
Prior art date
Application number
IL11173094A
Other languages
English (en)
Hebrew (he)
Other versions
IL111730A0 (en
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939324479A external-priority patent/GB9324479D0/en
Priority claimed from GB9402010A external-priority patent/GB9402010D0/en
Priority claimed from GB9412708A external-priority patent/GB9412708D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of IL111730A0 publication Critical patent/IL111730A0/xx
Publication of IL111730A publication Critical patent/IL111730A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
IL11173094A 1993-11-29 1994-11-22 Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them IL111730A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939324479A GB9324479D0 (en) 1993-11-29 1993-11-29 Piperazine derivatives
GB9402010A GB9402010D0 (en) 1994-02-02 1994-02-02 Piperazine derivatives
GB9412708A GB9412708D0 (en) 1994-06-24 1994-06-24 Piperazine derivatives

Publications (2)

Publication Number Publication Date
IL111730A0 IL111730A0 (en) 1995-01-24
IL111730A true IL111730A (en) 1998-12-06

Family

ID=27266956

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11173094A IL111730A (en) 1993-11-29 1994-11-22 Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them

Country Status (17)

Country Link
US (1) US5670505A (da)
EP (1) EP0655442B1 (da)
JP (1) JP3129123B2 (da)
KR (1) KR100381535B1 (da)
CN (1) CN1041923C (da)
AT (1) ATE201401T1 (da)
AU (1) AU689504B2 (da)
CA (1) CA2136712A1 (da)
DE (1) DE69427266T2 (da)
DK (1) DK0655442T3 (da)
ES (1) ES2156588T3 (da)
GR (1) GR3035923T3 (da)
HU (1) HUT71348A (da)
IL (1) IL111730A (da)
PH (1) PH31647A (da)
PT (1) PT655442E (da)
TW (1) TW384287B (da)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0636130A1 (en) * 1992-04-15 1995-02-01 Merck Sharp & Dohme Ltd. Azacyclic compounds
US5883098A (en) * 1993-11-29 1999-03-16 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
DE69615670T2 (de) * 1995-03-15 2002-08-08 Aventis Pharmaceuticals Inc., Bridgewater Heterocyclisch substituierte piperazonderivate als tachykinin rezeptor antagonisten
JP4173912B2 (ja) * 1995-05-02 2008-10-29 シェーリング コーポレイション ニューロキニンアンタゴニストとしてのピペラジノ誘導体
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
US5719156A (en) * 1995-05-02 1998-02-17 Schering Corporation Piperazino derivatives as neurokinin antagonists
CN1072220C (zh) * 1995-05-25 2001-10-03 藤泽药品工业株式会社 作为神经激肽受体拮抗剂的1－苯甲酰基－2－(吲哚基－3－烷基)－哌嗪衍生物
GB9510600D0 (en) * 1995-05-25 1995-07-19 Fujisawa Pharmaceutical Co Piperazine derivatives
US5654316A (en) * 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
US5892039A (en) * 1995-08-31 1999-04-06 Schering Corporation Piperazino derivatives as neurokinin antagonists
BR9610277A (pt) * 1995-08-31 1999-07-06 Schering Corp Derivados de piperazino como antagonistas de neurowuinina
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
JP2000502100A (ja) * 1995-12-18 2000-02-22 藤沢薬品工業株式会社 タキキニン拮抗薬としてのピペラジン誘導体
US5869488A (en) * 1996-05-01 1999-02-09 Schering Corporation Piperazino derivatives as neurokinin antagonists
TR199901570T2 (xx) * 1996-10-30 1999-09-21 Schering Corporation N�rokinin antagonistleri olarak piperazin t�revleri
US5968929A (en) * 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
GB9702194D0 (en) * 1997-02-04 1997-03-26 Lilly Co Eli Sulphonide derivatives
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AUPO735997A0 (en) * 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
DE19737334A1 (de) * 1997-08-27 1999-03-04 Solvay Pharm Gmbh 7-Phenyl-1,4-diazepan-Derivate, sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
ATE396187T1 (de) * 1997-08-27 2008-06-15 Solvay Pharm Gmbh Indolmethyl-n,n'-bisacylpiperazine als neurokininrezeptorantagonisten
DE19824865A1 (de) * 1997-08-27 1999-03-04 Solvay Pharm Gmbh Neue Harnstoffderivate
PE20000943A1 (es) * 1998-07-31 2000-09-28 Lilly Co Eli Derivados de sulfonamida
US6693137B1 (en) 1998-07-31 2004-02-17 Eli Lilly And Company Sulphonamide derivatives
JP3454427B2 (ja) 1998-12-14 2003-10-06 藤沢薬品工業株式会社 ピペラジン誘導体
GB9905010D0 (en) 1999-03-04 1999-04-28 Merck Sharp & Dohme Therapeutic agents
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
FR2810033B1 (fr) 2000-06-08 2004-04-30 Oreal Nouveaux composes de la famille des n-acylamino-amides, compositions les comprenant, et utilisations
TW591025B (en) * 2000-06-13 2004-06-11 Fujisawa Pharmaceutical Co Production of the piperazine derivative
JP2004501903A (ja) 2000-06-29 2004-01-22 藤沢薬品工業株式会社 ベンズヒドリル誘導体
GB0017256D0 (en) 2000-07-13 2000-08-30 Merck Sharp & Dohme Therapeutic agents
IT1318650B1 (it) * 2000-07-28 2003-08-27 Dompe Spa 1,3-diossolani ad attivita' antitosse.
IT1318651B1 (it) * 2000-07-28 2003-08-27 Dompe Spa Sintesi di (+-)1,3-diossolani e loro risoluzione ottica.
DE10036818A1 (de) * 2000-07-28 2002-02-07 Solvay Pharm Gmbh Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
UA75425C2 (en) 2001-07-09 2006-04-17 Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
US6974869B2 (en) * 2001-09-18 2005-12-13 Bristol-Myers Squibb Pharma Company Piperizinones as modulators of chemokine receptor activity
EP1295599A1 (en) * 2001-09-21 2003-03-26 Boehringer Ingelheim International GmbH Method for the treatment of prevention of atopic dermatitis
EP1436281B1 (en) * 2001-10-17 2010-06-16 Schering Corporation Piperidine- and piperazineacetamides as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2003037271A2 (en) * 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US7482365B2 (en) 2002-02-08 2009-01-27 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases
UA77515C2 (en) * 2002-04-04 2006-12-15 Diazabicyclo alkane derivatives possessing neuroldnin-nk1 receptor antagonistic activity
TW200514785A (en) * 2003-09-26 2005-05-01 Solvay Pharm Bv Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity
BRPI0608847A2 (pt) 2005-03-08 2010-02-02 Janssen Pharmaceutica Nv derivados de diaza-espiro-[4,4]-nonano substituìdos e seu uso como antagonistas de neurocinina
EP2233470B1 (en) 2005-07-04 2011-12-07 High Point Pharmaceuticals, LLC Histamine H3 receptor antagonists
JP2009537596A (ja) * 2006-05-23 2009-10-29 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ６−（４−シクロプロピルピペリジン−１−イル）−２’−メチル−［３，４’］−ビピリジン及びその医薬としての使用
SG163547A1 (en) * 2006-05-29 2010-08-30 High Point Pharmaceuticals Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
EP2149373A1 (en) * 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. 5HT7 receptor ligands and compositions comprising the same
KR101169719B1 (ko) 2009-06-09 2012-07-30 연세대학교 산학협력단 피페라진 이미노 구조를 갖는 화합물을 포함하는 혈관신생 억제용 약제학적 조성물
US8946197B2 (en) 2009-11-16 2015-02-03 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof
WO2012071469A2 (en) * 2010-11-23 2012-05-31 Nevada Cancer Institute Histone demethylase inhibitors and uses thereof for treatment o f cancer
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
JP6473133B2 (ja) * 2013-03-15 2019-02-20 アラクセス ファーマ エルエルシー Ｋｒａｓｇ１２ｃの共有結合性阻害剤
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CN107849022A (zh) 2015-04-10 2018-03-27 亚瑞克西斯制药公司 取代的喹唑啉化合物和其使用方法
EP3283462B1 (en) 2015-04-15 2020-12-02 Araxes Pharma LLC Fused-tricyclic inhibitors of kras and methods of use thereof
EP3291813A4 (en) 2015-05-06 2019-01-02 The Regents of The University of California K-ras modulators
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356351A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10414757B2 (en) 2015-11-16 2019-09-17 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
CN110036010A (zh) 2016-09-29 2019-07-19 亚瑞克西斯制药公司 Kras g12c突变蛋白的抑制剂
CN110312711A (zh) 2016-10-07 2019-10-08 亚瑞克西斯制药公司 作为ras抑制剂的杂环化合物及其使用方法
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
TW201900638A (zh) 2017-04-20 2019-01-01 加州大學董事會 Ｋ－ｒａｓ調節劑
EP3630747A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Quinazoline derivatives as modulators of mutant kras, hras or nras
TW201906832A (zh) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 用於癌症治療之化合物及其使用方法
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
EP4371613A3 (en) 2018-02-26 2024-07-24 Ospedale San Raffaele S.r.l. Compounds for use in the treatment of ocular pain
CN108409627B (zh) * 2018-03-14 2021-11-23 河北科技大学 含吲哚片段的乙酰芳腙类衍生物及其应用
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency
WO2022246115A1 (en) * 2021-05-19 2022-11-24 Cornell University Apt1 and apt2 inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3132882A1 (de) * 1981-08-20 1983-03-03 Cassella Ag, 6000 Frankfurt Neue piperazinone, ihre herstellung und verwendung
US4997836A (en) * 1988-11-11 1991-03-05 Takeda Chemical Industries, Ltd. Trisubstituted piperazine compounds, their production and use
DK0411150T3 (da) * 1989-02-10 1996-12-16 Otsuka Pharma Co Ltd Indolderivater
GB8908587D0 (en) * 1989-04-15 1989-06-01 Scras Societe De Conseils De R New 2-substituted n,n'-ditrimethoxybenzoyl piperazines
WO1992020661A1 (en) * 1991-05-22 1992-11-26 Merck & Co., Inc. N, n-diacylpiperazines
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
GB9222486D0 (en) * 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
CA2165176A1 (en) * 1993-06-18 1995-01-05 Samuel L. Graham Inhibitors of farnesyl-protein transferase

Also Published As

Publication number Publication date
CN1041923C (zh) 1999-02-03
KR950014097A (ko) 1995-06-15
DE69427266T2 (de) 2001-09-13
CN1107149A (zh) 1995-08-23
HU9403414D0 (en) 1995-02-28
PH31647A (en) 1999-01-12
JP3129123B2 (ja) 2001-01-29
AU7911194A (en) 1995-06-08
EP0655442A1 (en) 1995-05-31
DE69427266D1 (de) 2001-06-28
DK0655442T3 (da) 2001-07-30
US5670505A (en) 1997-09-23
HUT71348A (en) 1995-11-28
GR3035923T3 (en) 2001-08-31
EP0655442B1 (en) 2001-05-23
JPH07242641A (ja) 1995-09-19
IL111730A0 (en) 1995-01-24
KR100381535B1 (ko) 2003-08-19
ATE201401T1 (de) 2001-06-15
PT655442E (pt) 2001-09-28
CA2136712A1 (en) 1995-05-30
AU689504B2 (en) 1998-04-02
TW384287B (en) 2000-03-11
ES2156588T3 (es) 2001-07-01

Similar Documents

Publication Publication Date Title
IL111730A (en) Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
US6087357A (en) Piperazine derivatives as tachykinin antagonists
JP3071829B2 (ja) ニューロキニン受容体拮抗剤としての１−ベンゾイル−２−（インドリル−３−アルキル）−ピペラジン誘導体
AU700693B2 (en) Novel substituted piperazine derivatives having tachykinin receptor antagonists activity
RU2258702C2 (ru) Производные ароилпиперазина, способ их получения, фармацевтическая композиция на их основе и способ лечения
US5883098A (en) Piperazine derivatives
AU718984B2 (en) Novel carboxy substituted cyclic carboxamide derivatives
US5597845A (en) Substituted alkyldiamine derivatives
AU743723B2 (en) Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists
JP2003513104A (ja) Ｎｏｓ阻害活性を有する置換ジペプチド
MXPA99011778A (en) Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists
MXPA98004887A (en) Piperazine derivatives as taquicin antagonists
JPH1081671A (ja) 新規ペプチド化合物

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees